Gosset Ownership
Public
Employees
~20
Therapeutic Areas
Stage
Phase 3
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Auspex Pharmaceuticals General Information
SD‑809 (deutetrabenazine), a VMAT2 inhibitor developed using deuterium chemistry, showed promise in pivotal Phase 2/3 trials for tardive dyskinesia and Huntington's chorea with improved safety and dosing profile compared to existing therapies. Topline data from key trials were expected around mid‑2015[6][9]. The drug has been commercialized under the brand name Austedo by Teva post-acquisition.
Contact Information
Primary Industry
Biotech
Corporate Office
La Jolla, California
United States
United States
Drug Pipeline
deutetrabenazine
Phase 3Key Partnerships
Acquired by Teva; no other major partnerships explicitly noted pre-acquisition[2]
Auspex Pharmaceuticals Funding
No funding data available
To view Auspex Pharmaceuticals's complete valuation and funding history, request access »
Auspex Pharmaceuticals Financial Metrics
Market Cap
$41127.6M
Total Revenue
$3981.0M
Enterprise Value
$54293.7M